DR. ALAN N. HOUGHTON, M.D.
Osteopathic Medicine at York Ave, New York, NY

6719974, Apr 13, 2004

Oct 5, 2000

09/680806

James E. Rothman - New York NY
Franz Ulrich Hartl - Kottgeisering, DE
Mee H. Hoe - Irvington NY
Alan Houghton - New York NY
Yoshizumi Takeuchi - Kobe, JP
Mark Mayhew - New York NY

Sloan-Kettering Institute for Cancer Research - New York NY

A61K 3900

4241851, 4241931, 42419511, 42419611, 42419711, 4242771, 4242781, 514 2, 514 24, 530412, 530413, 530828

The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.

2002015, Oct 24, 2002

Jan 7, 2002

10/041410

Alan Houghton - New York NY, US
Clariss Naftzger - San Carlos CA, US
Vijayasaradhi Setaluri - Winston-Selem NC, US

A61K039/00, A61K038/19

424/085100, 424/184100, 424/277100

Tolerance of the immune system for self differentiation antigens can be overcome and an immune response stimulated by administration of a therapeutic differentiation antigen. The therapeutic differentiation antigen is altered with respect to the target differentiation antigen in the individual being treated (i.e., the differentiation antigen to which an immune response is desired) in one of three ways. First, the therapeutic differentiation antigen may be syngeneic with the target differentiation antigen, provided that therapeutic differentiation antigen is expressed in cells of a species different from the individual being treated. For example, a human differentiation antigen expressed in insect or other non-human host cells can be used to stimulate an immune response to the differentiation antigen in a human subject. Second, the therapeutic differentiation antigen may be a mutant form of a syngeneic differentiation antigen, for example a glycosylation mutant. Third, the therapeutic differentiation antigen may be a differentiation antigen (wild-type or mutant) of the same type from a species different from the individual being treated. For example, a mouse differentiation antigen can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of altered antigens in accordance with the invention results in an effective immunity against the original antigen expressed by the cancer in the treated individual.

2010006, Mar 18, 2010

Nov 19, 2009

12/622096

Alan N. Houghton - New York NY, US
Clarissa Naftzger - Belmont CA, US

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

A61K 9/127, A61K 39/00, A61K 31/7052, A61P 37/04

424450, 4241841, 514 44 R

Tolerance of the immune system for endogenous PSMA can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed PSMA antigen. For example, mouse PSMA, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against PSMA expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing PSMA, such as prostate cancer.

2004009, May 20, 2004

Mar 11, 2003

10/386994

James Rothman - New York NY, US
F. Hartl - Munich, DE
Mee Hoe - New York NY, US
Alan Houghton - New York NY, US
Yoshizumi Takeuchi - Kobe, JP
Mark Mayhew - Tarrytown NY, US

A61K048/00, A61K009/127, C12N015/86, C12N015/88

514/044000, 424/450000, 435/456000, 435/458000, 435/459000

Administration of expressible polynucleolides encoding eukaryotic heat shock proteins to mammalian cells leads to the stimulation of an immune response to antigens present in those cells. This makes it possible to stimulate an immune response to target antigens, including target tumor antigens or antigens associated with an infectious disease, without having to isolate a unique antigen or antigen-associated heat shock protein for each target antigen by administering to a mammalian subject or to a group of mammalian cells containing the antigen, an expressible polynucleotide encoding a heat shock protein. The expressed heat shock protein may have the same structure as native heat shock proteins, or may have a modified form adapted to control the trafficking of the expressed heat shock protein within the cells.

6328969, Dec 11, 2001

May 21, 1999

9/308697

Alan N. Houghton - New York NY
Clarissa Naftzger - San Carlos CA

Sloan-Kettering Institute for Cancer Research - New York NY

A61K 3908, A61K 4800, A01N 6300, A01N 6500, C12Q 100

4241841

Tolerance of the immune system for self differentiation antigens can be overcome and an immune response stimulated by administration of a therapeutic differentiation antigen. The therapeutic differentiation antigen is altered with respect to the target differentiation antigen in the individual being treated (i. e. , the differentiation antigen to which an immune response is desired) in one of three ways. First, the therapeutic differentiation antigen may be syngeneic with the target differentiation antigen, provided that therapeutic differentiation antigen is expressed in cells of a species different from the individual being treated. For example, a human differentiation antigen expressed in insect or other non-human host cells can be used to stimulate an immune response to the differentiation antigen in a human subject. Second, the therapeutic differentiation antigen may be a mutant form of a syngeneic differentiation antigen, for example a glycosylation mutant. Third, the therapeutic differentiation antigen may be a differentiation antigen (wild-type or mutant) of the same type from a species different from the individual being treated.

2010006, Mar 18, 2010

Nov 19, 2009

12/622103

Alan N. Houghton - New York NY, US
Clarissa Naftzger - Belmont CA, US

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

A61K 9/127, A61K 39/00, A61K 31/7052, A61P 37/04

424450, 4241841, 514 44 R

Tolerance of the immune system for endogenous TRP2 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed TRP2 antigen. For example, mouse TRP2, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against TRP2 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing TRP2, such as melanoma.

2004007, Apr 15, 2004

Feb 14, 2003

10/367668

James Rothman - New York NY, US
Franz-Ulrich Hartl - Kottgeisering, DE
Mee Hoe - Irvington NY, US
Alan Houghton - New York NY, US
Yoshizumi Takechi - Kobe City, JP
Mark Mayhew - New York NY, US

A61K039/00

424/185100

The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.

4613576, Sep 23, 1986

Mar 9, 1983

6/473830

Richard J. Cote - New York NY
Donna M. Morrissey - New York NY
Alan N. Houghton - New York NY
Edward J. Beattie - New York NY
Herbert F. Oettgen - New Canaan CT
Lloyd J. Old - New York NY

Sloan-Kettering Institute for Cancer Research - New York NY

C12N 1500, C12N 500, G01N 3353, C12P 2100

436548

Hybridomas which produce human monoclonal antibodies are disclosed. The hybridomas are formed by fusing lymphocytes from individuals with various cancers to an immortal cell line, such as a myeloma, from, e. g. , a human cell line, or a mouse cell line.

2003019, Oct 16, 2003

Jan 17, 2002

10/053498

James Rothman - New York NY, US
Mark Mayhew - Tarrytown NY, US
Mee Hoe - New York NY, US
Alan Houghton - New York NY, US
Ulrich Hartl - Munich, DE
Ouathek Ouerfelli - New York NY, US
Yoichi Moroi - New York NY, US

A61K039/395, G01N033/53, A61K031/33, C07K016/46

424/178100, 514/183000, 435/007100, 530/391100

The present invention relates (i) to conjugate peptides engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response in a subject in need of such treatment. It is based, at least in part, on the discovery of tethering molecules which may be used to non-covalently link antigenic peptides to heat shock proteins. The present invention also provides for methods of identifying additional tethers which may be comprised, together with antigenic sequences, in conjugate peptides.